RxDoctor Payments Data

Gregory Thoreson, MD

Urology · Dallas, TXNPI 1093034126

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (39.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 50 manufacturers reported payments, led by Intuitive Surgical at 25.3% of the total.

$28,028in general payments, 2019–2025

Across 357 payments — averaging $78.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$7K
  • Pfizer$4K
  • Novartis$4K
  • Bayer$4K
  • Johnson & Johnson$2K
  • Janssen Scientific Affairs, LLC$2K
  • plus $6K from 44 others
$133,535in research payments, 2019–2025

Across 49 payments — averaging $2725.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$73K
  • Sumitomo Pharma America, Inc.$41K
  • Merck$19K

What the payments were for

  • Consulting fees$11,15340%
  • Travel & lodging$6,67624%
  • Food & beverage$8,52030%
  • Education$1,6796%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,028 in reported general payments places this provider in the 85th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$421,276
Medicare patients
664
Services billed
5,370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix185$474,759
MyrbetriqMirabegron191$150,478
Abiraterone Acetate27$83,529
GemtesaVibegron36$38,926
Mirabegron ErMirabegron29$21,229
Tamsulosin Hcl641$9,713
Finasteride569$9,343
Tadalafil44$4,851
Silodosin27$3,312
Testosterone35$3,157
Cefdinir135$2,378
Testosterone Cypionate40$1,540
Oxybutynin Chloride ErOxybutynin Chloride40$912
Potassium Citrate ErPotassium Citrate14$802
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav55$525

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$504$513,685221 claims
Astellas Pharma US IncMyrbetriq$816$150,478191 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$1,530$83,52927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 878 urology providers in Texas.

Other urology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →